Business Overview (Details) - USD ($)		1 Months Ended		6 Months Ended
	Jan. 14, 2022	Mar. 31, 2022	Oct. 31, 2018	Jun. 30, 2022	Jun. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
First milestone payment			$ 1,000,000	$ 2,000,000	$ 0
Merger Agreement, Upon Receipt of Phase II Positive Data
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments payable	$ 3,000,000
Merger Agreement, Upon Initiation of Phase III Trial
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments payable	5,000,000
CEO
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
First milestone payment	800,000		$ 300,000
Number of shares issued (in shares)			603
Petrus Wijngaard, Director of Company
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
First milestone payment			$ 2,805
Number of shares issued (in shares)			6
Aurinia
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
First milestone payment			$ 300,000
Ciclofilin
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
First milestone payment	$ 2,000,000		$ 700,000
Number of shares issued (in shares)		4,317	1,439
Issuance of common stock in conjunction with milestone payment			$ 55,398
Percentage of issued and outstanding common stock	7.50%		2.50%
Ciclofilin | Merger Agreement, Upon Acceptance By FDA of New Drug
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments payable	$ 5,000,000